Does Rallies show Form 4 insider transactions for UPB?

Yes. Rallies tracks UPB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is UPB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for UPB. It does not provide personalized investment advice.

UPB (Upstream Bio, Inc. Common Stock) Stock Analysis - Insider Trades

Upstream Bio, Inc. Common Stock (UPB) is a publicly traded Healthcare sector company. As of May 21, 2026, UPB trades at $8.41 with a market cap of $463.11M and a P/E ratio of -3.12. UPB moved +4.61% today. Year to date, UPB is -67.81%; over the trailing twelve months it is -7.89%. Its 52-week range spans $5.14 to $33.68. Analyst consensus is strong buy with an average price target of $45.00. Rallies surfaces UPB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading UPB stock inside the company?

Recent UPB insider activity includes GRAY MICHAEL sold 852, Deykin Aaron sold 894, Sutherland Everett Rand sold 2.09K, Ambrose Allison sold 475, and Houghton Adam sold 699. Rallies tracks insider transaction dates, shares, prices, and estimated values.

UPB Key Metrics

Key financial metrics for UPB
Metric	Value
Price	$8.41
Market Cap	$463.11M
P/E Ratio	-3.12
EPS	$-2.66
Dividend Yield	0.00%
52-Week High	$33.68
52-Week Low	$5.14
Volume	0
Avg Volume	0
Revenue (TTM)	$2.85M
Net Income	$-143.44M
Gross Margin	0.00%

Recent UPB Insider Trades

GRAY MICHAEL sold 852 (~$7.92K) on Mar 16, 2026.
Deykin Aaron sold 894 (~$8.31K) on Mar 16, 2026.
Sutherland Everett Rand sold 2.09K (~$19.44K) on Mar 16, 2026.
Ambrose Allison sold 475 (~$4.41K) on Mar 16, 2026.
Houghton Adam sold 699 (~$6.49K) on Mar 16, 2026.

Latest UPB News

Upstream Bio Holds $294.6M Cash, Targets Q1 2027 Phase 3 Asthma and CRSwNP Trials — May 13, 2026
Upstream Bio to Present Phase 2 VIBRANT Verekitug Data on Nasal Polyps and Asthma — Apr 17, 2026
Upstream Bio to Launch Phase 3 Verekitug Trials in Severe Asthma and CRSwNP with $341.5M Cash — Mar 26, 2026
Upstream Bio’s Verekitug Lowers Nasal Polyp Score by 1.95 and Cuts Rescue Use 76% — Mar 1, 2026
Upstream Bio to present additional Phase 2 VIBRANT trial analyses on March 1 — Feb 26, 2026

UPB Analyst Consensus

8 analysts cover UPB: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.00.

Common questions about UPB

Who is trading UPB stock inside the company?: Recent UPB insider activity includes GRAY MICHAEL sold 852, Deykin Aaron sold 894, Sutherland Everett Rand sold 2.09K, Ambrose Allison sold 475, and Houghton Adam sold 699. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for UPB?: Yes. Rallies tracks UPB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is UPB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for UPB. It does not provide personalized investment advice.